证券代码：603301 证券简称：振德医疗 公告编号：2025-046 振德医疗用品股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2026年第一次临时股东会 召开的日期时间：2026 年 1 月 5 日 14 点 00 分 召开地点：浙江省绍兴市越城区皋埠街道香积路 55 号振德医疗用品股份有 限公司会议室 (五) 网络投票的系统、起止日期和投票时间。 股东会召开日期：2026年1月5日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 1 月 5 日 至2026 年 1 月 5 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当 ...

证券代码：603301 证券简称：振德医疗 公告编号：2025-043 振德医疗用品股份有限公司 第四届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案已经公司第四届董事会薪酬与考核委员会第一次会议、审 计委员会第五次会议审议通过。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2、审议通过《关于变更公司住所及修改<公司章程>并办理工商 变更登记的议案》，董事会同意变更公司住所及修改《公司章程》事 项，并提请股东会授权公司经营层办理变更公司住所及修改《公司章 程》工商变更登记手续（最终以市场监督管理局核准的内容为准）。 《公司章程》修改情况如下： | 序号 | 修改前 | 修改后 | | --- | --- | --- | | | 第五条 公司住所：浙江省绍兴市 | 第五条 公司住所：浙江省绍兴市越 | | 1 | 越城区皋埠街道皋北工业区，邮编： | 城区皋埠街道香积路 55 号，邮编： | | | 312035。 | 312035 ...

Core Insights - The global adhesive bandage market is projected to reach a sales value of $2.33 billion in 2024 and is expected to grow to $3.45 billion by 2031, with a compound annual growth rate (CAGR) of 6.15% [3] - The market expansion is driven by increasing consumer health awareness, the proliferation of home healthcare, and continuous innovation in functional adhesive bandage products [3] Market Overview - The European market is currently the largest consumer of adhesive bandages, accounting for 32.60% of global consumption in 2024, followed by North America at 30.19% and China at 11.06% [3] - China's market is expected to grow significantly, reaching $445 million by 2031, with its global market share increasing to 12.89% due to rising consumer spending and healthcare improvements [3] - Southeast Asia is anticipated to be the fastest-growing emerging market, with a CAGR of 9.75% from 2025 to 2031 [3] Production Insights - China and North America are the two major manufacturing hubs for adhesive bandages, with China expected to account for 64.23% of global production in 2024 [4] - By 2031, China's production share is projected to increase to 66.84%, indicating a shift from a manufacturing center to a hub for brand output and technological innovation [4] Product Structure - Hydrocolloid adhesive bandages dominate the global market, expected to reach a market share of 56.55% by 2031, driven by their superior breathability and moisture retention properties [4] - The trend towards high-end products is evident, particularly in the European and North American markets [4] Sales Channels - Online sales are becoming a significant growth driver, with an estimated market share of 8.78% in 2024 and a projected CAGR of 20.46% in the coming years [4] - The development of e-commerce platforms enhances consumer convenience and provides brands with greater market visibility and data-driven marketing capabilities [4] Competitive Landscape - The global adhesive bandage market is characterized by high concentration, with Kenvue holding approximately 36.94% of the market share in 2024 [7] - Major competitors include Beiersdorf, 3M, and Medline Industries, collectively holding about 36.81% of the market [7] - Future growth areas include functional adhesive bandages, children's bandages, and sports protection bandages [7] Industry Drivers - The rise in health consciousness among consumers is leading to increased demand for adhesive bandages in daily life [8] - Technological advancements in materials and processes are enhancing product performance and comfort, thereby boosting industry growth [8] - Regulatory standards in the medical device sector are influencing industry development, focusing on product quality, safety, and environmental considerations [8] Challenges - The adhesive bandage industry faces intense price competition due to low entry barriers, leading to compressed profit margins [10] - Brand homogenization is prevalent, with many products lacking significant differentiation, which can result in price wars [10] - Consumer loyalty is low, as adhesive bandages are low-cost items, making consumers more susceptible to price and promotional influences [10] - Stricter regulations in the medical device sector pose risks for companies that fail to comply with quality and safety standards [10]

Core Viewpoint - The stock of Zhendemedical (603301) experienced a decline of 2.28% on December 10, 2025, closing at 72.37 yuan, with significant net outflows from major funds and a mixed performance from retail investors [1][2]. Group 1: Stock Performance and Trading Data - On December 10, 2025, Zhendemedical's trading volume was 70,200 hands, with a total transaction amount of 504 million yuan [1]. - The net outflow of major funds was 31.21 million yuan, accounting for 6.19% of the total transaction amount, while retail investors saw a net inflow of 17.17 million yuan, representing 3.41% of the total [1][2]. - Over the past five days, the stock has seen fluctuations in net fund flows, with a notable net inflow of 106 million yuan on December 9, 2025, followed by a significant outflow on December 10 [2]. Group 2: Financing and Margin Trading Data - On December 10, 2025, the financing balance was 1.45 billion yuan, with a net repayment of 11.43 million yuan [3]. - The margin trading data indicates a total margin balance of 1.45 billion yuan, with a short selling of 600 shares and a remaining short position of 14,500 shares [3]. Group 3: Company Financials and Industry Comparison - For the first three quarters of 2025, Zhendemedical reported a main business revenue of 3.184 billion yuan, a year-on-year increase of 1.88%, but a net profit of 203 million yuan, down 33.91% year-on-year [5]. - The company's gross profit margin stands at 33.93%, significantly lower than the industry average of 51.22%, ranking 97th out of 124 in the medical device industry [5]. - Zhendemedical's total market capitalization is 19.239 billion yuan, with a price-to-earnings ratio of 71.01, which is higher than the industry average of 62.74 [5].

Core Viewpoint - Zhendemedical (603301.SH) reported a closing price of 69.20 yuan, with a decline of 5.99% [1] Group 1: Company Performance - Huachuang Securities analysts noted that Zhendemedical's profit growth is temporarily pressured by a high base, but acquisitions are opening new growth opportunities [1] - The analysts maintained a "strong buy" rating for Zhendemedical [1]

Market Overview - On December 4, A-shares showed mixed performance with the three major indices fluctuating. The total market turnover was 1.56 trillion yuan, a decrease of over 120 billion yuan compared to the previous trading day. More than 1,400 stocks closed higher, with 40 stocks hitting the daily limit up [1]. Sector Performance - The electric motor concept led the gains, with Sanxie Electric rising over 17%. Other sectors such as reducers, state-owned fund holdings, and aviation engines also saw increases. In contrast, sectors like Hainan, tourism and hotels, and dairy products experienced the largest declines [1]. Institutional Ratings - Five stocks received buy ratings from institutions today, including Zhend Medical, New Town Holdings, and Shanxi Fenjiu. The average decline for these stocks was 1.37%, underperforming the Shanghai Composite Index. The largest declines were seen in Shanxi Fenjiu (3.42%), Zhend Medical (2.50%), and New Town Holdings (1.42%) [1]. Institutional Buying and Selling - In the Dragon and Tiger list, 15 stocks were net bought, with 11 stocks net sold. Nine stocks had net purchases exceeding 10 million yuan, led by Heertai with a net buy of 330 million yuan. The largest net sell was in Aerospace Development, with a net sell of 364 million yuan [4][5]. Northbound Capital Flow - Northbound funds saw net purchases in 10 stocks, with Heertai leading at 188 million yuan. Conversely, nine stocks experienced net selling, with Tongyu Communications facing the highest net sell of 146 million yuan [6][7]. Important Announcements - ST Xianhe announced the removal of risk warnings and a name change to "Xianhe Environmental Protection." Zhongbai Group closed 30 large warehouse stores, expecting a loss of 180 million yuan. China Petroleum signed contracts worth 40 billion yuan to acquire 100% equity in three gas storage companies [8].

Core Viewpoint - Zhend Medical reported a net profit of 203 million yuan for Q1-Q3 2025, representing a decrease of 33.91%, with Q3 net profit at 75 million yuan, down 48.47% [1] Financial Performance - The revenue showed steady growth, while profits faced temporary pressure due to high base effects [1] - The company is entering the respiratory and anesthesia equipment sector through acquisitions, which opens new growth opportunities [1] Future Outlook - Zhend Medical aims to build a broader and deeper healthcare industry chain to support the development of high-quality medical services [1] - Based on the analysis of the Q3 report, long-tail product optimization, and expense input rhythm, the company is valued at 26.8 billion yuan, with a target price of approximately 101 yuan, maintaining a "strong buy" rating [1]

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 101 CNY, while the current price is 75.50 CNY [3]. Core Insights - The company's revenue for the first three quarters of 2025 reached 3.184 billion CNY, reflecting a growth of 1.88%, while the net profit attributable to shareholders was 203 million CNY, down 33.91% year-on-year [2][3]. - The decline in net profit is attributed to a high base effect from the previous year, where a significant asset disposal contributed approximately 93 million CNY to the net profit [3]. - The company has entered the respiratory and anesthesia equipment sector through the acquisition of Ningbo Shengyu Rui Medical Equipment Co., which is expected to enhance its product offerings and market penetration [3]. Financial Performance Summary - For the first three quarters of 2025, the company reported: - Total revenue of 3.184 billion CNY (+1.88%) - Net profit of 203 million CNY (-33.91%) - Non-recurring net profit of 183 million CNY (-18.79%) [2]. - In Q3 2025, the company achieved: - Revenue of 1.084 billion CNY (+0.10%) - Net profit of 75 million CNY (-48.47%) - Non-recurring net profit of 65 million CNY (+2.00%) [2]. - Financial projections for 2024A to 2027E indicate a gradual increase in total revenue from 4.264 billion CNY in 2024 to 5.332 billion CNY in 2027, with corresponding net profits expected to rise from 385 million CNY to 395 million CNY [2][3]. Valuation Metrics - The projected P/E ratios for 2025E, 2026E, and 2027E are 65, 59, and 52 respectively, while the P/B ratios are expected to be 3.6, 3.4, and 3.3 [2][3]. - The report estimates the company's overall valuation at 26.8 billion CNY based on DCF modeling [3].

Core Viewpoint - Zhendemedical has shown significant stock performance with a year-to-date increase of 269.26%, indicating strong market interest and potential growth in the medical supplies sector [1][2]. Financial Performance - For the period from January to September 2025, Zhendemedical reported a revenue of 3.184 billion yuan, reflecting a year-on-year growth of 1.88%. However, the net profit attributable to shareholders decreased by 33.91% to 203 million yuan [2]. - The company has distributed a total of 1.46 billion yuan in dividends since its A-share listing, with 706 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 25, Zhendemedical's stock price reached 78.80 yuan per share, with a market capitalization of 20.996 billion yuan. The stock experienced a net inflow of 26.7841 million yuan from major funds [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) four times this year, with the latest appearance on November 17, where it recorded a net buy of 329,100 yuan [1]. Shareholder Information - As of September 30, 2025, Zhendemedical had 23,600 shareholders, an increase of 4.06% from the previous period. The average number of circulating shares per shareholder decreased by 3.90% to 11,308 shares [2][3]. - Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 3.9382 million shares, which is an increase of 190,000 shares from the previous period [3].

Core Points - Zhendemedical (603301) closed at 77.25 yuan on November 24, 2025, with a market capitalization of 20.583 billion yuan, reflecting a 2.33% increase from the previous trading day [1] - The stock opened at 75.27 yuan, reached a high of 77.29 yuan, and a low of 74.39 yuan, with a trading volume of 4.91 billion yuan and a turnover rate of 2.42% [1] Company Actions - Zhendemedical announced the implementation of a partial share repurchase and cancellation related to its first employee stock ownership plan, due to unmet performance targets for the third unlocking period [1] - The company decided to repurchase and cancel 615,667 shares at a price of 25.16 yuan per share, funded by its own resources [1] - This repurchase and cancellation were completed on November 27, 2025, reducing the total share capital from 266,451,202 shares to 265,835,535 shares [1] - The action does not affect the company's financial status, operating results, or listing status, and does not harm the interests of the company and its shareholders [1]